Review
Urology & Nephrology
Nicholas G. Zaorsky, Jeremie Calais, Stefano Fanti, Derya Tilki, Tanya Dorff, Daniel E. Spratt, Amar U. Kishan
Summary: Biochemical recurrence after radical prostatectomy is common in intermediate-risk and high-risk prostate cancer patients. The optimal management includes a comprehensive evaluation with novel techniques like PET imaging and genomic analysis, along with consideration of traditional clinical variables. Salvage radiotherapy is the only known curative intervention for these patients without metastatic disease, but the importance of accurate timing, radiation dose, and systemic therapy must be emphasized.
NATURE REVIEWS UROLOGY
(2021)
Review
Oncology
Ziqi Yu, Mei Song, Lotfi Chouchane, Xiaojing Ma
Summary: Metastasis remains the leading cause of death in breast cancer patients worldwide, with genomic profiling methods revolutionizing our understanding of this complex process. There is a lack of accurate prognostic indicators and effective treatments for metastasis, highlighting the importance of recent advancements in functional genomic analysis for potential prognostic and therapeutic implications.
Review
Oncology
Mario Terlizzi, Elaine Johanna Limkin, Yasmina Moukasse, Pierre Blanchard
Summary: The management of patients with biochemical recurrence after prostatectomy has changed significantly in recent years. Close monitoring of prostate-specific antigen (PSA) and early salvage radiotherapy (RT) have become the standard of care. However, uncertainties remain regarding the management of high-risk patients and the role of imaging.
Review
Oncology
Jake Drobner, Alain Kaldany, Mihir S. Shah, Saum Ghodoussipour
Summary: This review aims to evaluate the role of salvage radical prostatectomy in patients with prostate cancer recurrence after initial radiotherapy. Radical prostatectomy has shown oncologic benefits but also carries the risk of functional complications. There is no consensus on the optimal salvage approach for localized prostate cancer recurrence, but the review suggests that salvage radical prostatectomy can offer meaningful cancer control for select patients with radiation-resistant disease.
Article
Medicine, General & Internal
Constantinos Zamboglou, Jan C. Peeken, Ali Janbain, Sandrine Katsahian, Iosif Strouthos, Konstantinos Ferentinos, Andrea Farolfi, Stefan A. Koerber, Juergen Debus, Marco E. Vogel, Stephanie E. Combs, Alexis Vrachimis, Alessio Giuseppe Morganti, Simon K. B. Spohn, Mohamed Shelan, Daniel M. Aebersold, Anca-Ligia Grosu, Francesco Ceci, Christoph Henkenberens, Stephanie G. C. Kroeze, Matthias Guckenberger, Stefano Fanti, Claus Belka, Peter Bartenstein, George Hruby, Sophia Scharl, Thomas Wiegel, Louise Emmett, Armelle Arnoux, Nina-Sophie Schmidt-Hegemann
Summary: This study developed and validated a nomogram for predicting freedom from biochemical failure (FFBF) after PSMA-PET-based salvage radiotherapy (sRT). By retrospectively analyzing 1029 patients, factors associated with FFBF were identified and a accurate nomogram was generated. The nomogram showed good consistency in internal and external validation.
Review
Oncology
Mohammad Abufaraj, Abdelmuez Siyam, Mustafa Rami Ali, Rodrigo Suarez-Ibarrola, Lin Yang, Beat Foerster, Shahrokh F. Shariat
Summary: Local salvage therapies for radiation recurrent prostate cancer can lead to impaired urinary and sexual functions, but the likelihood of these sequalae may be predictable based on the patient's pre-salvage general health status. Despite the adverse consequences, the use of local salvage therapies may be justified for local disease control, but decision-making should involve informed patient input in a shared process.
Article
Oncology
Philipp Gild, Raisa S. Pompe, Thomas Seisen, Jacob Keeley, Hoang J. Tang, Alberto Bossi, Derya Tilki, Mani Menon, Firas Abdollah
Summary: The study compared early versus late salvage radiotherapy for biochemical recurrence after radical prostatectomy by simulating a randomized trial, and found that early treatment did not improve metastasis-free survival.
EUROPEAN UROLOGY ONCOLOGY
(2021)
Article
Urology & Nephrology
Alexandar Blazevski, Bart Geboers, Matthijs J. Scheltema, William Gondoputro, Paul Doan, Athos Katelaris, Shikha Agrawal, Daniela Baretto, Jayne Matthews, Anne-Maree Haynes, Warick Delprado, Ron Shnier, Willemien van den Bos, James E. Thompson, Nathan Lawrentschuk, Phillip D. Stricker
Summary: This multicenter trial aimed to evaluate the safety, functional, and oncological outcomes of salvage irreversible electroporation (IRE) for radio-recurrent focal prostate cancer. The results showed that IRE treatment had minimal toxicity and promising functional and oncological outcomes for patients.
Article
Oncology
Lorenzo Bianchi, Francesco Ceci, Eleonora Balestrazzi, Francesco Costa, Matteo Droghetti, Pietro Piazza, Alessandro Pissavini, Massimiliano Presutti, Andrea Farolfi, Riccardo Mei, Paolo Castellucci, Giorgio Gandaglia, Alessandro Larcher, Daniele Robesti, Alexandre Mottrie, Alberto Briganti, Alessio Giuseppe Morganti, Stefano Fanti, Francesco Montorsi, Riccardo Schiavina, Eugenio Brunocilla
Summary: In this study, researchers retrospectively analyzed 113 patients with recurrent prostate cancer after radical prostatectomy and salvage therapies. The study found that patients who underwent second-line PSMA-guided metastases-directed therapy (MDT) had better outcomes in terms of metastases-free survival and castration-resistant prostate cancer-free survival compared to those who received conventional management.
Article
Oncology
Jonathan D. Tward, Thorsten Schlomm, Stephen Bardot, Daniel J. Canter, Troy Scroggins, Stephen J. Freedland, Lauren Lenz, Darl D. Flake, Todd Cohen, Michael K. Brawer, Steven Stone, Jay Bishoff
Summary: The study evaluated a score combining a genomic expression classifier and clinical information to predict progression to metastatic disease in men with prostate cancer. It found that some patients could safely forgo multimodal therapy, and validated the effectiveness of the combined clinical cell-cycle risk score in assessing disease progression risk in patients.
CLINICAL GENITOURINARY CANCER
(2021)
Article
Endocrinology & Metabolism
Yilin Cao, Daniel Y. Song, Curtiland Deville, Theodore L. DeWeese, Stephen Greco, Phuoc T. Tran, Matthew P. Deek
Summary: This study investigated the rate of prostate bed recurrence in oligometastatic prostate cancer patients after metastasis-directed therapy. The results showed that patients who did not receive prostate bed irradiation had a higher rate of local failure. Prospective studies are needed to determine when prostate bed irradiation should be considered for patients with oligometastatic prostate cancer after radical prostatectomy.
Article
Oncology
Frank C. Cackowski, Elisabeth I. Heath
Summary: Prostate cancer has the unique ability to lie dormant and recur long after treatment, with important reservoirs for dormant tumor cells in the bone marrow, lymph nodes, and the prostate bed. The induction of cellular dormancy in prostate cancer cells involves complex signaling pathways and interactions with the microenvironment, and current adjuvant therapies are only modestly successful in preventing recurrence, indicating the need for further advancements in systemic adjuvant therapy.
Article
Urology & Nephrology
Bart Geboers, Matthijs J. Scheltema, Alexandar Blazevski, Athos Katelaris, Paul Doan, Imran Ali, Shikha Agrawal, Daniela Barreto, Jayne Matthews, Anne-Maree Haynes, Warick Delprado, Ron Shnier, James E. Thompson, Phillip D. Stricker
Summary: This study evaluated the safety, oncological outcomes, and quality of life (QoL) of focal irreversible electroporation (IRE) in patients with radio-recurrent prostate cancer. The results showed that IRE treatment can achieve oncological control and improve the QoL of patients.
Review
Urology & Nephrology
Luca F. Valle, Eric J. Lehrer, Daniela Markovic, David Elashoff, Rebecca Levin-Epstein, R. Jeffery Karnes, Robert E. Reiter, Matthew Rettig, Jeremie Calais, Nicholas G. Nickols, Robert T. Dess, Daniel E. Spratt, Michael L. Steinberg, Paul L. Nguyen, Brian J. Davis, Nicholas G. Zaorsky, Amar U. Kishan
Summary: In the management of locally recurrent prostate cancer after definitive radiotherapy, salvage treatment modalities show similar 5-yr recurrence-free survival rates compared to RP, but reirradiation may result in lower toxicity.
Article
Oncology
Laila A. Gharzai, Ralph Jiang, David Wallington, Gavin Jones, Samuel Birer, Neil Jairath, Elizabeth M. Jaworski, Matthew R. McFarlane, Brandon A. Mahal, Paul L. Nguyen, Howard Sandler, Todd M. Morgan, Zachery R. Reichert, Joshi J. Alumkal, Rohit Mehra, Amar U. Kishan, Karim Fizazi, Susan Halabi, Edward M. Schaeffer, Felix Y. Feng, David Elliott, Robert T. Dess, William C. Jackson, Matthew J. Schipper, Daniel E. Spratt
Summary: This study comprehensively assessed the performance of commonly reported intermediate clinical endpoints in all randomized trials in localized prostate cancer, and found that metastasis-free survival is the only identified surrogate endpoint for overall survival to date.
Editorial Material
Oncology
Nadine A. Friedrich, Stephen J. Freedland, Ilona Csizmadi
PROSTATE CANCER AND PROSTATIC DISEASES
(2023)
Article
Oncology
Zachary Klaassen, Lauren Howard, Christopher J. D. Wallis, Jessica L. Janes, Amanda De Hoedt, William J. Aronson, Thomas J. Polascik, Christopher J. Amling, Christopher J. Kane, Matthew R. Cooperberg, Martha K. Terris, Yuan Wu, Stephen J. Freedland
Summary: In patients with biochemical recurrence after radical prostatectomy, the progression to castration-resistant prostate cancer (CRPC) may serve as a potential intermediate endpoint for developing metastatic disease. Based on the study results, there is a high correlation between CRPC-free survival (CRPC-FS) and metastasis-free survival (MFS), suggesting that CRPC-FS could potentially be used as an intermediate endpoint in trials for patients with biochemical recurrence initiating androgen deprivation therapy.
PROSTATE CANCER AND PROSTATIC DISEASES
(2023)
Article
Medicine, Research & Experimental
Celina H. Shirazipour, Carolina Raines, Marcio A. Diniz, Sarah-Jeanne Salvy, Robert W. Haile, Stephen J. Freedland, Arash Asher, Jennifer R. Tomasone, Gillian Gresham
Summary: Increased physical activity, improved sleep, and decreased sedentary behavior are crucial for cancer survivors. However, efforts to promote and measure these behaviors have been limited. The 24-Hour movement approach, which views physical activity, sedentary behavior, and sleep as a continuum, has potential benefits for clinical trial design and integration of wearable technology in oncology.
CONTEMPORARY CLINICAL TRIALS COMMUNICATIONS
(2023)
Article
Oncology
Andrei Sergeyev, Lin Gu, Amanda M. De Hoedt, Christopher L. Amling, William J. Aronson, Matthew R. Cooperberg, Christopher J. Kane, Zachary Klaassen, Martha K. Terris, Lourdes Guerrios-Rivera, Stephen J. Freedland, Ilona Csizmadi
Summary: The study found that diabetes identified by ICD-9/10 codes was associated with better overall survival in late-stage prostate cancer patients, while the "undiagnosed" diabetes identified by high HbA1c values was associated with an increase in all-cause mortality. In addition, the duration of diabetes prior to diagnosis was inversely associated with prostate cancer-specific mortality.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
(2023)
Article
Endocrinology & Metabolism
Jordan J. Kramer, Lin Gu, Daniel Moreira, Gerald Andriole, Stephen J. Freedland, Ilona Csizmadi
Summary: In older men, smoking does not increase the risk of developing lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH) in asymptomatic men, nor does it affect the progression of LUTS in symptomatic men.
Article
Endocrinology & Metabolism
Victor Pereira, Taofik Oyekunle, Jessica Janes, Christopher J. Amling, William J. Aronson, Matthew R. Cooperberg, Christopher J. Kane, Martha K. Terris, Zachary Klaassen, Stephen J. Freedland, Adriana C. Vidal, Ilona Csizmadi
Summary: A study of 5885 patients at eight Veterans Affairs Hospitals found no significant differences in waiting time for prostate cancer treatment between Black and White men.
Editorial Material
Oncology
Gillian Gresham, Carolina Raines, Arash Asher, Stephen J. Freedland, Celina H. Shirazipour, Alix G. Sleight
PROSTATE CANCER AND PROSTATIC DISEASES
(2023)
Article
Oncology
Ivy T. Liu, Lin Gu, Amanda M. De Hoedt, Matthew R. Cooperberg, Christopher L. Amling, Christopher J. Kane, Zachary Klaassen, Martha K. Terris, Lourdes Guerrios-Rivera, Adriana C. Vidal, William J. Aronson, Stephen J. Freedland, Ilona Csizmadi
Summary: This research examined the associations between obesity and various outcomes of prostate cancer, such as biochemical recurrence, metastasis, castrate resistant-PC, PCSM, and ACM. The study also investigated if smoking modified these associations. The results showed that obesity was associated with an increased risk of PCSM, while overweight and obesity were inversely associated with ACM. Additionally, the associations between BCR and ACM were modified by smoking status.
CANCER CAUSES & CONTROL
(2023)
Review
Oncology
Stephen J. Freedland, Imtiaz A. Samjoo, Emily Rosta, Austin Lansing, Evelyn Worthington, Alexander Niyazov, Jonathan Nazari, Bhakti Arondekar
Summary: This systematic literature review explores the impact of race on survival in patients with metastatic prostate cancer. The study found that Black, Hispanic, and American Indian/Alaskan Native patients had similar survival rates as White patients, while Black patients on certain treatments and Asian patients showed improved survival rates.
PROSTATE CANCER AND PROSTATIC DISEASES
(2023)
Meeting Abstract
Oncology
Maral DerSarkissian, Deepshekhar Gupta, Jasmina Ivanova, Alexander Niyazov, Enrico Zanardo, Tracy Guo, Jingru Wang, Mei Sheng Duh, Stephen J. Freedland
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Meeting Abstract
Oncology
Maral DerSarkissian, Deepshekhar Gupta, Jasmina Ivanova, Alexander Niyazov, Enrico Zanardo, Tracy Guo, Jingru Wang, Mei Sheng Duh, Stephen J. Freedland
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Meeting Abstract
Oncology
Stephen J. Freedland, Alexander Niyazov, Jonathan Nazari, Evelyn Worthington, Austin Lansing, Emily Rosta, Imtiaz Samjoo
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Meeting Abstract
Oncology
Stephen J. Freedland, Marty Chakoian, Edward Wells, Nader N. El-Chaar, Alexandra Colon, Dina Elsounda, Agnes Hong
JOURNAL OF CLINICAL ONCOLOGY
(2023)